3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
110
Carcinoma, Non-Small-Cell Lung
63
Lung Neoplasms
27
Hodgkin Disease
14
Lymphoma
10
Neoplasm Metastasis
9
Triple Negative Breast Neoplasms
8
Neoplasms
8
Recurrence
7
Prostatic Neoplasms
7
Small Cell Lung Carcinoma
5
Sarcoma
5
Rhabdomyosarcoma
5
Lymphoma, Large B-Cell, Diffuse
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Breast Neoplasms, Male
4
Brain Neoplasms
4
Adenocarcinoma of Lung
4
Ovarian Neoplasms
3
NSCLC
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Esophageal Squamous Cell Carcinoma
3
Interventions
Fulvestrant
6
olaparib
4
Letrozole
4
trastuzumab deruxtecan
3
Aromatase Inhibitors
3
Anastrozole
3
sacituzumab govitecan
2
pyrotinib
2
eribulin
2
dalpiciclib
2
Paclitaxel
2
Goserelin
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Capecitabine
2
toripalimab
1
talazoparib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
elacestrant
1
disitamab vedotin
1
ceralasertib
1
capivasertib
1
balixafortide
1
apatinib
1
abemaciclib
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Breast Cancer
×
Vinorelbine
×
Clear all
NCT04304352
2023-06-28
VEX
European Institute of Oncology
Phase 2
Unknown
162 enrolled